Investor Relations Home
Portola Pharmaceuticals, Inc. was founded in 2003 and is headquartered in South San Francisco, Calif. We completed an initial public offering in May 2013 and are traded on the Nasdaq Stock Market under the symbol PTLA. We have approximately 95 employees.More >>
|06/24/15||Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin Complex Concentrate Did Not|
|Data Presented at International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress
SOUTH SAN FRANCISCO, Calif., June 24, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced results of a study demonstrating that andexanet alfa significantly reduced bleeding in a validated animal model of bleeding using the Factor Xa inhibitor rivaroxaban as the anticoagulant. The reduction in blood loss correlated with reversal of the anticoagulant effects of rivaroxaban as mea... |
|06/22/15||Portola, Bristol-Myers Squibb and Pfizer Announce Full Results of Second Part of Phase 3 ANNEXA-A(TM) Study Demonstrating That Investigational Andexanet Alfa Sustained Reversal of Anticoagulant Effect of Factor Xa Inhibitor Eliquis (apixaban)|
|Data Presented Today in Late-Breaking Clinical Trial Oral Session at International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress
SOUTH SAN FRANCISCO, Calif., PRINCETON, N.J. and NEW YORK, June 22, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA), Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced full results from the second part of the Phase 3 ANNEXA™-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors – A... |
|06/15/15||Portola Pharmaceuticals Appoints Industry Leader Tao Fu as Executive Vice President, Chief Commercial and Business Officer|
|Addition Strengthens Leadership Team as Company Advances Three Potentially Groundbreaking Products in Thrombosis and Hematologic Cancer
SOUTH SAN FRANCISCO, Calif., June 15, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced the appointment of Tao Fu as executive vice president, chief commercial and business officer, effective immediately. Mr. Fu joins Portola from Bristol-Myers Squibb (BMS), where he was vice president and head of mergers and acquisitions and allian... |
|06/09/15||Portola Pharmaceuticals Announces Upcoming Data Presentations on Andexanet Alfa at International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress |
|--Full Results of Second Part of ANNEXA™-Apixaban Study and Results of Andexanet Alfa Vs. Four-Factor Prothrombin Complex Concentrate Study to be Featured in Oral Sessions--
South San Francisco, Calif. (June 9, 2015) – Portola Pharmaceuticals (Nasdaq: PTLA) today announced that data from its clinical development program for the investigational agent andexanet alfa will be highlighted in oral sessions at the upcoming International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress... |
|06/03/15||Portola Pharmaceuticals to Present at Goldman Sachs 36th Annual Global Healthcare Conference|
|SOUTH SAN FRANCISCO, Calif., June 3, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that William Lis, chief executive officer, will present at the Goldman Sachs 36th Annual Global Healthcare Conference on Wednesday, June 10, at 8:00 a.m. Pacific Time in Rancho Palos Verdes, Calif.
The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section.
About Portola Pharmaceuticals, Inc.
|There are currently no events scheduled.|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.